Ketamine for the Treatment of Depression in Parkinson's Disease
What is the purpose of this trial?
The main purpose of this study is to examine the efficacy, safety and mechanistic underpinnings of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.
A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
- Trial withMichael J. Fox Foundation
- Ages40 years - 70 years
- Last Updated09/29/2023
- Study HIC#2000030394